Medrol and Ocular toxicity - a phase IV clinical study of FDA data

Summary:

Ocular toxicity is reported as a side effect among people who take Medrol (methylprednisolone), especially for people who are female, 40-49 old, also take Amlodipine, and have Cutaneous vasculitis.

The phase IV clinical study analyzes which people have Ocular toxicity when taking Medrol. It is created by eHealthMe based on reports of 23,951 people who have side effects when taking Medrol from the FDA, and is updated regularly.

What is Medrol?

Medrol has active ingredients of methylprednisolone. It is often used in rheumatoid arthritis. eHealthMe is studying from 24,443 Medrol users. Check the latest studies of Medrol.

What is Ocular toxicity?

Ocular toxicity (damages eye) is found to be associated with 65 drugs and 118 conditions by eHealthMe. Check the latest studies of Ocular toxicity.

On Jul, 08, 2026

23,951 people reported to have side effects when taking Medrol.
Among them, 14 people (0.06%) have Ocular toxicity.

Among these 14 people:

What is the gender of people who have Ocular toxicity when taking Medrol? *

female: 100 %
male: 0.0 %

What is the age of people who have Ocular toxicity when taking Medrol? *

What are other drugs people take besides Medrol? *

What are other side effects people have besides Ocular toxicity? *

Vasculitic Rash (inflammation of a blood vessel or blood vessels with rashes under the skin): 14 people, 100.00%
Swelling: 14 people, 100.00%
Skin Discoloration: 14 people, 100.00%
Eye Infection: 14 people, 100.00%
Drug Ineffective: 14 people, 100.00%
C-Reactive Protein Increased: 14 people, 100.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 14 people, 100.00%
Abdominal Pain: 14 people, 100.00%
Drug Effect Decreased: 1 person, 7.14%

What are the existing conditions these people have? *

Cutaneous Vasculitis (an inflammatory process affecting the vessel wall that leads to its damage): 14 people, 100.00%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 13 people, 92.86%

* Approximation only. Some reports may have incomplete information.

Do you take Medrol and have Ocular toxicity?

- Check whether Ocular toxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Medrol:

Medrol (24,443 reports)

Browse all side effects of Medrol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ocular toxicity:

Ocular toxicity (65 drugs)

Browse all the conditions that are associated with Ocular toxicity:

Ocular toxicity (118 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methylprednisolone (the active ingredients of Medrol) and Medrol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.